Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent intraday, after Sanofi finally pulled the trigger on the development of ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Zacks Investment Research on MSN
Recursion's Q3 earnings beat estimates on Sanofi milestone revenues
Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated ...
Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.
Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...
Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results